Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining Prognostic Markers and Clinical Outcomes in Epithelioid Malignant Peripheral Nerve Sheath Tumor.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Effectiveness and outcome of gracilis muscle flap reconstruction following perineal surgery: a retrospective single-center cohort study.

Annals of medicine and surgery (2012)·2026
Same author

Rethinking the <sup>2</sup>H fingerprint of carbohydrates: a novel proxy for plant metabolism and performance.

The New phytologist·2025
Same author

Hot and Hungry - High temperatures induce changes in leaf carbon dynamics and sugar isotope fingerprints.

NPJ science of plants·2025
Same author

Gut microbiota predict development of postdischarge diabetes mellitus in acute pancreatitis.

Gut·2025

Related Experiment Video

Updated: May 27, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Gastrointestinal stromal tumors.

Alexander W Beham1, Inga-Marie Schaefer, Philipp Schüler

  • 1Department of Surgery, University of Göttingen, Robert Koch Str. 42, 37075, Göttingen, Germany.

International Journal of Colorectal Disease
|November 30, 2011
PubMed
Summary

Gastrointestinal stromal tumors (GIST) are common but resistant to traditional treatments. Imatinib mesylate is a key therapy, but surgery remains the only cure, with adjuvant therapy recommended for high-risk cases.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Experiment Videos

Last Updated: May 27, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Area of Science:

  • Gastrointestinal stromal tumors (GIST)
  • Oncology
  • Molecular targeted therapy

Background:

  • GIST is the most common mesenchymal tumor of the intestinal tract.
  • GIST is often refractory to conventional chemotherapy and radiation.
  • Pathogenesis involves KIT and PDGFRA gene mutations, activating oncoproteins.

Purpose of the Study:

  • To summarize the current understanding of GIST treatment.
  • To highlight the role of imatinib mesylate in GIST therapy.
  • To discuss factors influencing GIST recurrence and management strategies.

Main Methods:

  • Review of existing literature on GIST pathogenesis and treatment.
  • Analysis of therapeutic outcomes with imatinib mesylate.
  • Identification of risk factors for GIST recurrence post-surgery.

Main Results:

  • Imatinib mesylate inhibits KIT kinase activity and is a cornerstone therapy for GIST.
  • Complete surgical removal is the only curative option, but recurrence is common.
  • Adjuvant therapy with tyrosine kinase inhibitors is recommended for high-risk patients.

Conclusions:

  • Imatinib mesylate offers significant response rates (around 80%) for unresectable and advanced GIST.
  • Risk stratification for recurrence involves surgical and tumor-associated factors.
  • Adjuvant imatinib mesylate is crucial for high-risk GIST patients post-resection.